The evolving UK landscape surrounding mind-altering substances is increasingly complex, demanding careful navigation. While clinical research into compounds like psilocybin and copyright continues to progress, and patient access via private clinics is increasing, the regulatory framework remains uncertain. This presents a distinctive situation f… Read More